180
Participants
Start Date
October 31, 1998
Study Completion Date
March 31, 2003
bexarotene
Memorial Sloan-Kettering Cancer Center, New York
University of Pennsylvania Cancer Center, Philadelphia
Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington D.C.
Cancer Center, University of Virginia HSC, Charlottesville
Baptist Regional Cancer Institute - Jacksonville, Jacksonville
Mayo Clinic Jacksonville, Jacksonville
Sylvester Cancer Center, University of Miami, Miami
University of Alabama Comprehensive Cancer Center, Birmingham
Sarah Cannon-Minnie Pearl Cancer Center, Nashville
Arthur G. James Cancer Hospital - Ohio State University, Columbus
Hematology Oncology Consultants Inc, Columbus
Michigan State University, East Lansing
University of Minnesota, Minneapolis
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
University of Arkansas for Medical Sciences, Little Rock
University of Texas - MD Anderson Cancer Center, Houston
Arizona Cancer Center, Tucson
Beckman Research Institute, City of Hope, Los Angeles
Kaiser Permanente-Southern California Permanente Medical Group, San Diego
Cancer Research Center of Hawaii, Honolulu
USC/Norris Comprehensive Cancer Center, Los Angeles
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
UCSF Cancer Center and Cancer Research Institute, San Francisco
Yale Comprehensive Cancer Center, New Haven
Louisiana State University School of Medicine, New Orleans
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
University of Nebraska Medical Center, Omaha
Oregon Cancer Center at Oregon Health Sciences University, Portland
University of Texas Health Science Center at San Antonio, San Antonio
Lead Sponsor
Ligand Pharmaceuticals
INDUSTRY